On and off metronomic oral vinorelbine in elderly women with advanced breast cancer

Tumori

Volumn 101, Issue 1, 2015, Pages 30-35

  De Iuliis, Francesca ^a   Salerno, Gerardo ^a   Taglieri, Ludovica ^a   Lanza, Rosina ^b   Scarpa, Susanna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Elderly patients; FACT B test; Metastatic breast cancer; Metronomic therapy; Quality of life; Vinorelbine

Indexed keywords

ANTHRACYCLINE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; ANASTROZOLE; ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; FULVESTRANT; LAPATINIB; LETROZOLE; MONOCLONAL ANTIBODY; NITRILE; PROGESTERONE RECEPTOR; QUINAZOLINE DERIVATIVE; TAXOID; TRIAZOLE DERIVATIVE; TUMOR MARKER; VINBLASTINE;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST METASTASIS; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; PATIENT COMPLIANCE; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMISTRY; CLINICAL TRIAL; METRONOMIC DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DEOXYCYTIDINE; ESTRADIOL; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM GRADING; NEOPLASM STAGING; NITRILES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 84930732324     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000207     Document Type: Article

References (20)

1. Van de Water W, Bastiaannet E, Egan KM, et al. Management of primary metastatic breast cancer in elderly patients, an international comparison of oncogeriatric versus standard care. J Geriatr Oncol. 2014;5(3):252-259.
2. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-436.
3. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49(16):3387-3395.
4. Aapro M, Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev. 2012;38(2):120-126.
5. Nolè F, Crivellari D, Mattioli R, et al. Phase II study of an alloral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2009;64(4):673-680.
6. Briasoulis E, Aravantinos G, Kouvatseas G, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013;13(1): 263-275.
7. Briasoulis E, Pappas P, Puozzo C, et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res. 2009;15(20):6454-6461.
8. Saridaki Z, Malamos N, Kourakos P, et al. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2012;69(1):35-42.
9. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol. 2008; 19(2):212-222.
10. Bartsch R, Wenzel C, Pluschnig U, et al. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol. 2006; 57(5):554-558.
11. Baweja M, Suman VJ, Fitch TR, et al; NCCTG. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol. 2006;17(4):623-629.
12. Addeo R, Sgambato A, Cennamo G, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010;10(4):301-306.
13. Cazzaniga ME, Torri V, Villa F, et al. Efficacy and safety of the all- oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the Phase I-II VICTOR-1 study. Int J Breast Cancer. 2014;2014: 769790.
14. Saloustros E, Kalbakis K, Vardakis N, et al. Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. J BUON. 2011;16(2):215-218.
15. Bartsch V. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma] [article in German]. Onkologie. 2006;29(Suppl 1):1-28.
16. Saridaki Z, Malamos N, Kourakos P, et al. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2012; 69(1):35-42.
17. Addeo R, Sperlongano P, Montella L, et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol. 2012;70(4):603-609.
18. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19(4): 1195-1206.
19. Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007; 7(6):566-581.
20. Laquente B, Viñals F, Germà JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol. 2007;9(2):93-98.